Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
about
Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimatesAngiotensin receptor blockers for heart failureAngiotensin receptor blockers and myocardial infarctionHeart failure with preserved ejection fraction: emerging drug strategiesDifferential clinical profile of candesartan compared to other angiotensin receptor blockersHeart Failure: Diagnosis, Management and UtilizationMicroRNA and Heart FailureTargeting heart failure with preserved ejection fraction: current status and future prospectsMechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle DisordersRecent advances in treatment of heart failureUnderstanding heart failure with preserved ejection fraction: where are we today?Breakthrough in heart failure with preserved ejection fraction: are we there yet?New Insights in the Diagnosis and Treatment of Heart FailureEffect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic ReviewChallenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm SocietyHeart failure in patients with chronic kidney disease: a systematic integrative reviewExercise intolerance in heart failure with preserved ejection fraction: more than a heart problemUnderstanding the epidemic of heart failure: past, present, and futureHeart failure with preserved ejection fraction: mechanisms, clinical features, and therapiesNeutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsPatient selection in heart failure with preserved ejection fraction clinical trialsScope of heart failure hospitalizationHeart Failure: a Major Cardiovascular Complication of Diabetes MellitusClinical Phenotypes in Heart Failure With Preserved Ejection FractionPresent and future pharmacotherapeutic agents in heart failure: an evolving paradigmAngiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyondClinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEMRole of angiotensin II in cardiovascular disease therapeutic implications of more than a century of researchAddressing the Heterogeneity of Heart Failure in Future Randomized Trials.Comparing angiotensin II receptor blockers on benefits beyond blood pressureEchocardiographic evaluation of diastolic heart failureHeart failure with normal ejection fraction: a growing pandemic.Heart failure with preserved ejection fraction.RAAS inhibitors and cardiovascular protection in large scale trials.A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitorsRenal impairment and heart failure with preserved ejection fraction early post-myocardial infarctionShould there be sex-specific criteria for the diagnosis and treatment of heart failure?Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia
P2860
Q24186056-F3AF9B45-95C9-437D-AE53-31AD52BC1C3EQ24199125-B3755CAB-2321-41E3-A21C-EF64C75DCDF1Q24559659-FF362614-8313-4DDA-8017-F80F54B83D66Q24595118-2D7F7FF3-3E3D-4529-A495-43728A695BB8Q24613321-3DCA459B-746D-417A-805A-13C26601F6C4Q26745543-692A4DE6-057B-4A05-87B3-25B9149C1623Q26750638-5FD8C474-07D0-4881-BD6E-F02FA7423707Q26752956-DDD31E71-2B28-4967-BA12-E1E25707F348Q26753129-CE4C422A-66E3-463E-8A79-D346F3A81B76Q26766223-612EBBD5-6AC3-431E-AED8-55CABC6C0690Q26766590-DD63FE51-B13D-49E3-97ED-64CB9051B2C4Q26771999-C4CDF1D4-5CB8-47B9-9C43-AF0F30D2A670Q26774884-A147663A-ADD9-495D-A397-E32A6539D9E7Q26783958-CFC82C89-6B58-4FD1-8A0E-AA0F7500AD08Q26785931-E1BC5988-82DA-43FC-9A28-BDF279F2FF48Q26796261-50889D9C-52EC-4A27-9CA9-227662DD49A9Q26824149-1CF28486-184D-4EDA-A894-5BC894032BD0Q26991985-59D4427E-849B-4B8E-A4B3-38302CFFFE23Q26996486-07340967-331B-47B0-B89A-F5591C73FF5AQ27000263-FADB0A8E-E2AA-42ED-83F0-BB5144861D97Q27004000-CF2F2338-6796-4A4E-8D41-503F6DEC0DE8Q27015845-4BE0AC67-AD45-4198-822E-F157404FFED1Q27022922-9A2A086B-AC87-43BA-B3DA-547415A6A4F4Q28066310-03486B5E-22E9-43DC-A48E-D1807695522AQ28073079-848E7092-E12D-478F-849B-3847FC84FEE0Q28077186-A7529E89-0DF0-4570-B106-7BA1996A4FB6Q28088583-3A8541D7-C3A8-4AFB-ABC6-1268EDDF9189Q28166022-65D5AB63-A2EB-439E-9E8F-DE1B621C015FQ28272171-C36834DB-8986-4D67-92D6-E660A6BE4FC8Q30234708-785296FB-4BBF-475A-ABF9-D0316C008053Q30360678-ADC8440A-43FE-491E-A497-57434C78414FQ30363544-61042486-2797-417D-8205-C97A054A87EFQ30417324-BA5FE5C9-E02F-4C09-B434-D9F08927000BQ30420528-7DEE6AAA-6710-4B7A-BF56-12F00DCBCB80Q30424541-A9C25CF6-E3D4-43D5-BB4B-7F8BCE4DAFEAQ30432209-60D6E290-580F-423F-8463-1DAEF670FDC4Q30434062-71EFD928-D98A-45E5-A18F-10996192D0BFQ30442043-639C1C02-5B05-4410-869F-DA46599C32BAQ30442221-C97A58F4-5EB1-4FDE-A9ED-08DE9E3D0871Q30450624-7851A70F-A7DC-4526-B83E-81684888DD1C
P2860
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effects of candesartan in pati ...... on: the CHARM-Preserved Trial.
@en
Effects of candesartan in pati ...... on: the CHARM-Preserved Trial.
@nl
type
label
Effects of candesartan in pati ...... on: the CHARM-Preserved Trial.
@en
Effects of candesartan in pati ...... on: the CHARM-Preserved Trial.
@nl
prefLabel
Effects of candesartan in pati ...... on: the CHARM-Preserved Trial.
@en
Effects of candesartan in pati ...... on: the CHARM-Preserved Trial.
@nl
P2093
P50
P1433
P1476
Effects of candesartan in pati ...... on: the CHARM-Preserved Trial.
@en
P2093
Bertil Olofsson
CHARM Investigators and Committees
Eric L Michelson
Jan Ostergren
John J V McMurray
Marc A Pfeffer
Peter Held
P304
P356
10.1016/S0140-6736(03)14285-7
P407
P577
2003-09-01T00:00:00Z